Tarsons Products Stock Hits All-Time Low Amid Prolonged Downtrend

On 20 Nov 2025, Tarsons Products closed near its 52-week low, just 2.12% above the lowest price of Rs 222.05 recorded during the past year. The stock experienced a day’s decline of 1.07%, contrasting with the Sensex’s modest gain of 0.20%. Despite an intraday high of Rs 231.85, representing a 3.53% rise, the overall trend remains firmly downward. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent weakness in price momentum.

Performance comparisons against the benchmark indices and sector peers reveal a consistent pattern of underperformance. Over the last week, Tarsons Products recorded a decline of 7.98%, while the Sensex advanced by 1.04%. The one-month and three-month periods show the stock falling by 23.71% and 32.89% respectively, whereas the Sensex posted gains of 1.17% and 4.27% over the same intervals. The disparity widens over longer durations, with the stock registering a 44.39% fall in the past year compared to the Sensex’s 10.02% rise. Year-to-date figures mirror this trend, with Tarsons Products down 45.22% against the Sensex’s 9.23% increase.

Examining the longer-term performance, Tarsons Products has underperformed the BSE500 index in each of the last three annual periods. Over three years, the stock has declined by 68.09%, while the Sensex has appreciated by 38.42%. The five- and ten-year figures show no gains for Tarsons Products, contrasting sharply with the Sensex’s 94.51% and 229.95% growth respectively. This prolonged underperformance highlights the challenges faced by the company in generating shareholder value over extended periods.

Financial results for the recent quarter ending September 2025 further illustrate the company’s difficulties. The Profit After Tax (PAT) stood at Rs 3.32 crores, reflecting a 51.8% reduction compared to the average of the previous four quarters. The Return on Capital Employed (ROCE) for the half-year period was recorded at 6.69%, the lowest level observed, indicating limited efficiency in generating returns from capital investments. Concurrently, the debt-to-equity ratio reached 0.41 times, the highest in recent periods, signalling a relatively increased reliance on debt financing.

Institutional investor participation has also shifted, with a decrease of 3.27% in their stake over the previous quarter. Currently, institutional investors hold 5.91% of the company’s shares. Given their capacity to analyse company fundamentals, this reduction may reflect a reassessment of the company’s prospects within professional investment circles.

Despite these challenges, the company’s ability to service its debt remains robust, with an average EBIT to interest coverage ratio of 12.03. This suggests that earnings before interest and taxes are sufficient to cover interest expenses comfortably. The valuation metrics also indicate a fair assessment, with a ROCE of 3.9 and an enterprise value to capital employed ratio of 1.6. The stock is trading at a discount relative to its peers’ historical valuations, which may reflect market caution given the company’s recent financial trajectory.

Profitability trends over the past year show a decline of approximately 30%, aligning with the stock’s negative return of 44.39% during the same period. This correlation between earnings contraction and share price movement underscores the financial pressures faced by Tarsons Products.

In summary, Tarsons Products has experienced a significant decline in its stock price, reaching an all-time low amid a backdrop of subdued financial performance and reduced institutional interest. The company’s recent quarterly results and long-term growth metrics highlight the extent of the challenges it faces within the Healthcare Services sector.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →